


Emergency Contraception Decision Aid



Abbreviations

BMI

body mass index

Cu-IUD

copper intrauterine device

ECP

emergency contraceptive pill

LNG

levonorgestrel

LNG-IUD

levonorgestrel intrauterine device

UPA

ulipristal acetate

Breastfeeding

No interruption of breastfeeding is necessary after a single dose of UPA¹²

Drug Interactions

UPA and LNG efficacy is reduced by CYP3A4 enzyme inducers [C]^{8,9,13}

Footnotes

[A] If unprotected sex occurred more than 5 days ago, refer to a provider who can discuss Cu-IUD or LNG-IUD 52mg placement.^{1,2,3,5}

[B] Limited but emerging data indicates that a LNG double dose (3 mg) may improve efficacy for obese patients.¹⁴ To date, this is not routinely recommended in clinical practice in the United States.

[C] European Medicines Agency recommends a LNG double dose (3 mg) with select concurrent CYP3A4 enzyme inducer(s). No change in dose is recommended for UPA.¹⁵

References

1. Turok D, Geoffrey E, Wojdyła D, Dermish A, Torres L, Wu S. Copper T380 intrauterine device for emergency contraception: highly effective at any time in the menstrual cycle. *Human Reproduction*. 2013;28(10):2672-76.
2. Thompson L, Sanders JN, Schwarz EB, Boras C, Turok DK. Copper intrauterine device placement 6-14 days after unprotected sex. *Contraception*. 2018;100(3):219-221.
3. Curtis KM, Jellison TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. *MMWR Recomm Rep*. 2016;65(No. RR-4):1-66.
4. Cleland K, Zhu H, Goldstick N, Cheng L, Trussell J. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. *Hum Reprod*. 2012;27(7):1994-2000.
5. Turok DK, Gera A, Simmons RG, et al. Levonorgestrel vs. copper intrauterine devices for emergency contraception. *N Engl J Med*. 2021;384:335-44.
6. Jellison TC, Curtis KM. Safety and effectiveness data for emergency contraceptive pills among women with obesity: a systematic review. *Contraception*. 2016;94(9):605-611.
7. Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. *Lancet*. 2010;375(9714):555-562.
8. HRA Pharma America Inc. Ella[®] [package insert]. Morrisstown, NJ 07960.

9. Foundation Consumer Healthcare, LLC. Plan B One-Step[®] [package insert]. Pittsburgh, PA 15205.
10. Barth C, Rutenber T, Duijkers L, et al. The effects on ovarian activity of delaying versus immediately restarting combined oral contraception after missing three pills and taking ulipristal acetate 30 mg. *Contraception*. 2020;102(3):145-151.
11. Brache V, Cochen L, Duijkers L, et al. A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception. *Hum Reprod*. 2015;30(12):2785-2793.
12. Drugs and Lactation Database (LactMed[®]) National Institute of Child Health and Human Development; 2006-. Ulipristal. 2026 Jan 18. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK500655/>
13. Le Corvaisier C, Capelle A, France M, Bourgaignon L, Tod M, Goutelle S. Drug interactions between emergency contraceptive drugs and cytochrome inducers: literature review and quantitative prediction. *Fundam Clin Pharmacol*. 2020.
14. Edelman AB, Cherala G, Blue SW, Erikson DW, Jensen JT. Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing. *Contraception*. 2016;94(1):52. Epub 2016 Mar 18.
15. European Medicines Agency. CHMP assessment report: Levonelle 1500 mcg tablets. Available at https://www.ema.europa.eu/en/documents/referral/levonelle-article-13-referral-chmp-assessment-report_en.pdf.